Medx Health Blockbuster Potential !
Optionen
| Boardmail an "2brix2" |
Wertpapier: Medx Health |
MedX Health verfügt über ein einzigartiges Produkt im Bereich Hautkrebs Früherkennung & Diagnostic. Die heutige News zum Thema Hautkrebs zeigt was die Gesellschaft in den kommenden Monaten und Jahren erwartet. Früherkennung und Diagnostic sind das A & O !
MedX wird signifikante Wachstumsraten erfahren.
http://www.turnto23.com/lifestyle/health/...n-cancer-seriously-062713
Skin cancer is a significant problem - worldwide. The skin cancers grow extremely. Timely detection of tumors by a good diagnostic is crucial. MedX Health will achieve strong revenue and profit growth in the coming months and years because of the increasing demand for skin cancer diagnostic devices. The market value of MedX is not even $ 2 million dollars. Given the significant growth rates far too little. I expect either an offer or milestone news. It's quite possible that it will soon be a strong price increase. The stock is undervalued at current Kursniveu. A target price of $ 0.50 CAD would be fairly current. Many skin cancers are caused by too frequent tanning sessions during the past 10 years require a reliable diagnostic. MedX the MoleMate system an important product in the field of skin cancer screening. Overall, the MedX product portfolio is extensive and very interesting. Starting from the laser therapy system to products in the field of cancer diagnostics. In addition, we announced new products. The company is set up easily wide, has a very very good products - Conclusion: the stock is significantly undervalued. Just then when nobody wants it to enter the stock at the time. Then, if the total mass of the crashes on the stock price is higher and the stock rises sharply. You can always buy shares at a time when no one wants to buy - at MedX one still has the chance.
http://boston.redsox.mlb.com/news/...270&vkey=pr_bos&c_id=bos
Some East Tennesseans had the chance to get an important health screening for free on Wednesday. The Skin Cancer Foundation made a stop in Kingston as part of its Healthy Skin Tour. Skin cancer is the most common form of cancer in the US with more than 3.5 million cases diagnosed each year. Local dermatologists volunteered their time to offer full body skin cancer screenings on the large tour RV. They also taught each person how to do self exams so they can perform monthly skin checks at home. "A patient should have their skin examined at least once a year. But I recommend checking your own skin once a month. So look for any moles that may be growing or changing or any small lesions that may bleed and not heal," said Dr. Elizabeth Anderson, a dermatologist.
Es werden ja außerdem wichtige Produktnews erwartet das dürfte erheblichen Schwung in der Aktie bringen
MoleMate™ Skin Cancer Imaging Mission Statement
http://simsys-molemate.com/about-medx/...r-imaging-mission-statement/
MedX Health Corporation’s mission is to provide innovative skin cancer imaging scanners that are portable, cost-effective, and provide critical information on every type of mole. At MedX our mission is to provide tools that use non-invasive and pain-free light to “See More”, and look 2mm below the surface of the skin, enabling physicians to scan suspicious moles via an “optical biopsy”, providing immediate feedback to patients, and improving the quality of care of potential cancer patients, by reducing the need for surgical biopsies, and the resulting pain, scars, and anxiety associated with waiting for biopsy results, as well as simplifying the early diagnosis of skin cancer, when it is most curable
Also die Aktie wird nun kräftig durchstarten. Die Nachfrage nach Hautkrebs Früherkennungsdiagnose Geräten wird erheblich steigen. MedX hat die Produkte auf diesem Gebiet.
Strong Buy MedX Health Corp.
Diese Empfehlung ist zwar aus Mitte 2012 aber aktueller den je .........
http://www.munknee.com/2012/05/...ment-in-your-health-and-your-wealth
This Skin Cancer Detection Device Could Be a Great Investment in Your Health – and Your Wealth I attended an investment presentation last week by a company that is introducing an innovative skin cancer detection device into the Canadian/American markets that was so enlightening, so potentially financially rewarding and so potentially life-saving, that I just have to share it with you. So says Lorimer Wilson, editor of www.munKNEE.com. Most of us enjoy getting a tan, even if it entails the occasional sunburn but, unfortunately, too much sun can eventually have an adverse affect on your health in the form of skin cancer which is growing at a rate of 10% per year. Indeed, the Canadian and US Cancer societies confirm that skin cancer is the most common form of cancer. Each year there are more new cases of skin cancer than the combined incidence of cancers of the breast, prostrate, lung and colon. Nearly 800,000 Americans are living with a history of melanoma and 13 million Americans are living with a history of non-melanoma skin cancer, typically diagnosed as basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). When melanoma is detected early, the survival rate is about 99% and falls to 15% as the disease advances. If you have experienced too many “too much sun” events over the years, however, (or you have some unchecked moles, or have a family history of malignant melanoma,) you may well be making regular visits to your dermatologist to have the unattractive – and potentially deadly – effects of too much sun (lesions, etc.) frozen off with the application of liquid nitrogen (called cryosurgery or cryotherapy) or otherwise treated ( the application of Efudex cream comes to mind). Some of you may have even: had an invasive and sometimes painful biopsy of a suspicious looking growth (mole, lesion or some other change in skin appearance), had to wait for weeks for the answer as to whether it was benign, skin cancer or malignant melanoma, had to schedule and wait for a follow-up appointment and then had to schedule, wait and undergo plastic surgery to repair the damage done by the biopsy. Unfortunately, I know of what I speak as I have been making quarterly visits over the past 20 years to my friendly and accomplished dermatologist undergoing the whole range of treatments. Well, no more! Future biopsies, and the need to wait for the results (an immediate diagnosis is made during your appointment) will be a thing of the past in large measure (see video here – 4:56 minutes) once family physicians and dermatologists begin practising a new non-invasive skin cancer screening procedure that has been in use in Europe, the UK, Australia for a number of years and has recently been introduced to the medical communities in Canada and the U.S. by MedX Health Corpoation (TSX-V:MDX). The system is the FDA approved and Health Canada cleared SIMSYS-MoleMate Skin Imaging System ( see a video here - 2:48 minutes – and here – 2:08 minutes) which provides a significant advance in the early detection of potentially life threatening moles and lesions. MoleMate uses a patented device and technology (MedX has been granted 17 international patents to date and has another 23 patents pending) that features a hand-held scanner designed for office use that utilizes light to view beneath suspicious moles or lesions in a pain free, non-invasive manner, creating images for physicians to evaluate all types of moles and lesions within seconds, providing images that can reveal if a mole is benign, or something more serious, often eliminating the need for skin biopsies, resulting in less pain, scarring, and expense. [See this video - 5:29 minutes - by Dr. Ronald H. Falcon, MD, FAAD on the merits of the SIMSYS-MoleMate.] It is just a matter of time before this system is owned by every family physician, dermatologist, clinic and hospital in North America so you can just imagine the upcoming growth and increased profits and share price of MedX Health Corp. MedX is a 12 year old Canadian company, headquartered in Mississauga, Ontario (Toronto). MDX trades on the TSX Venture Exchange under the symbol TSXV:MDX and currently trades in the $0.09 to $0.14 range as seen in the chart below:
CML HealthCare gets friendly $1.22-billion takeover offer from LifeLabs Medical
http://www.stockhouse.com/news/business-news/2013/...-billion-takeove
TORONTO - Two of Canada's largest medical lab operators will be combined under a $1.22 billion friendly takeover deal backed by one of Ontario's largest public sector pension funds.
http://www.emsc.com.au/generalPractice.htm
’Molemate’ computerised skin cancer assessments
On site visits are an important component of the health management of employees. We will visit your business for efficient management of:
• Molemate skin cancer screening for outdoor workers
Biocompatibles said that MoleMate enables GPs to offer the patients a quick diagnosis, addressing a major challenge in healthcare Biocompatibles said that MoleMate enables GPs to offer the patients a quick diagnosis, addressing a major challenge in healthcare
Biocompatibles International announced that a new UK and Australia study supported the use of MoleMate in the diagnosis of melanoma in primary care.
The AIM-listed drug-device specialist called the paper an important step forward for the technology as it moves towards commercialisation.
MoleMate is a non-invasive melanoma visualisation and assessment device, which incorporates SIAscopy, in the diagnosis of melanoma in primary care.
The investigators conducted an analysis of lesions for which histological diagnosis was available.
As a result, MoleMate had a better diagnostic accuracy in comparison with the "Seven Point Check-list" that is the current “gold standard” in primary care with the study showing a statistically significant difference (p = 0.02) in diagnostic accuracy against it.
The conclusions presented in the paper were drawn from data collected from six general practices in the UK and two primary care skin cancer clinics in Australia with a total 858 patients with 1,211 lesions recruited of which 1.2% were melanoma.
In another important conclusion, sensitivity, or correct identification of melanoma was similar in the UK and Australian groups, but the specificity, or correct identification of benign lesions was significantly better in the Australian group, suggesting that sun-related skin damage does not adversely affect the diagnostic accuracy of MoleMate.
The technology is very relevant, addressing a major challenge posed by melanoma diagnosis for general practitioners.
It was noted that GPs are less able than dermatologists to differentiate melanomas from other pigmented lesions as they did not encounter melanoma as frequently.
British data has shown that only 12% of referred lesions were diagnosed as skin cancer but that only 42% of skin cancers were referred by this route.
The authors commented that melanoma is responsible for 2% of cancers in the UK with about 8,000 new cases and 1,800 deaths a year, while Australia has the highest incidence of skin cancer worldwide and melanoma accounts for more than 10% of annual cancer incidence.
Worldwide, the incidence of melanoma is increasing faster than any other solid cancer.
Biocompatibles said that MoleMate enables GPs to offer the patients a quick diagnosis, delivering accurate results at an affordable cost.
“The importance of early and accurate diagnosis is well known. Melanoma is relatively easy to screen and typically fatal if detected late.
“This is a dangerous cancer and we need both GPs and dermatologists to be confident that the use of MoleMate in primary care offers a clear benefit to patients. This paper is an important step in this direction.
“But efficiency is the order of the day and the opportunity to reduce the 88% of referred lesions, which turn out to be benign, now seems pretty clear,” said chief executive of Biocompatibles Crispin Simon.
Biocompatibles has estimated that MoleMate is in use in more than 200 primary care clinics world-wide with more than 20,000 patients having been examined.
MoleMate is CE Marked and available throughout the EU and in other parts of the world, including Australia and New Zealand.
Biocompatibles is in the process of establishing a global distribution network.
In a trading statement released this week, Biocompatibles said that sales remained in line with management's expectations and it continued to expect full year revenue in the range of £31 million to £34 million.
Biocompatibles expects to exceed the year-end guidance for closing cash of £26 million.
“The company continues to make good progress and we look forward to achieving our 2010 annual goals,” said Simon.
Earlier this year, the company upped its full year guidance for revenues and closing cash.
Das UK System ist für die strenge Kosten-Nutzen-Kontrolle bekannt.
1. Value Health. 2013 Mar-Apr;16(2):356-66. doi: 10.1016/j.jval.2012.12.008.
The cost-effectiveness of a novel SIAscopic diagnostic aid for the management of
pigmented skin lesions in primary care: a decision-analytic model.
Wilson EC, Emery JD, Kinmonth AL, Prevost AT, Morris HC, Humphrys E, Hall PN,
Burrows N, Bradshaw L, Walls J, Norris P, Johnson M, Walter FM.
Health Economics Group, University of East Anglia, Norwich, UK.
ed.wilson@uea.ac.uk
OBJECTIVES: Pigmented skin lesions are commonly presented in primary care.
Appropriate diagnosis and management is challenging because the vast majority are
benign. The MoleMate system is a handheld SIAscopy scanner integrated with a
primary care diagnostic algorithm aimed at improving the management of pigmented
skin lesions in primary care.
METHODS: This decision-model-based economic evaluation draws on the results of a
randomized controlled trial of the MoleMate system versus best practice
(ISRCTN79932379) to estimate the expected long-term cost and health gain of
diagnosis with the MoleMate system versus best practice in an English primary
care setting. The model combines trial results with data from the wider
literature to inform long-term prognosis, health state utilities, and cost.
RESULTS: Results are reported as mean and incremental cost and quality-adjusted
life-years (QALYs) gained, incremental cost-effectiveness ratio with
probabilistic sensitivity analysis, and value of information analysis. Over a
lifetime horizon, the MoleMate system is expected to cost an extra £18 over best
practice alone, and yield an extra 0.01 QALYs per patient examined. The
incremental cost-effectiveness ratio is £1,896 per QALY gained, with a 66.1%
probability of being below £30,000 per QALY gained. The expected value of perfect
information is £43.1 million.
CONCLUSIONS: Given typical thresholds in the United Kingdom (£20,000-£30,000 per
QALY), the MoleMate system may be cost-effective compared with best practice
diagnosis alone in a primary care setting.
http://sco.lt/7V55V3
Zeitpunkt: 20.07.13 12:00
Aktion: Löschung des Beitrages
Kommentar: Regelverstoß - Bitte nur kurz zitieren und einen Link als Beleg angeben.
0.8/0.85
Hat jemand eine Seite für TSX Venture, wo man sieht wie der Kurs gestellt ist bzw sogar wieviel im Orderbuch drinn sind.
Optionen
| Boardmail an "2brix2" |
Wertpapier: Medx Health |
Bid/AKS 0.09/0.095
Da wissen wohl einige mehr....oder nur eine Blase?
Optionen
| Boardmail an "2brix2" |
Wertpapier: Medx Health |